STENTYS launches its initial public offering on NYSE Euronext Paris

- Opening of the public offering and the global placement in an indicative price range between 10.80 € and 13.20 € per share:
  - a public offering in France in the form of an open price offering, principally intended for individuals (the “Public Offering”); and
  - a global placement, principally intended for institutional investors (the “Global Placement”) in France and in certain other countries, outside of the United States of America
- Initial size of the offering: 1,893,939 newly issued shares, or 22.7 M€ (on the basis of the mid point of the initial public offering price range)
- An extension clause: up to 284,090 newly issued shares
- Over-allotment option: up to 326,704 newly issued shares
- Subscription period is expected to end on October 21st 2010, for both the Public Offering and the Global Placement
- Final offering price expected on October 22nd 2010, and trading on NYSE Euronext Paris expected on October 28th 2010

STENTYS launches today its initial public offering and proposed listing of its shares on NYSE Euronext Paris, C Compartment.

The French securities regulator (l’Autorité des marchés financiers – the AMF) granted visa n° 10-362 on October 12th 2010 to the prospectus relating to STENTYS’ initial public offering (comprising its Document de Base registered on September 9th, 2010 under number I.10-067, and a note d’opération, which includes a summary).

A NEW GENERATION OF STENTS

Founded in 2006, by Professor Jacques Séguin and Gonzague Issenmann, STENTYS is a medical technology company that develops a new generation of stents, to treat Acute Myocardial Infarction (AMI).

The STENTYS stent represents a major breakthrough compared to conventional stents when treating heart attack patients: it is self-expanding, i.e. it “fits snugly” into the contour of blood vessel, behaving as a spring once implanted; its shape and diameter adapt to the anatomic changes of the coronary arteries during the post-AMI phase.

By being in permanent contact with the vessel wall, the STENTYS stent avoids malapposition (“loosely” fit stent) observed with conventional stents, which can cause a second heart attack less than a month after the first one.

The STENTYS stent is now the most innovative and the safest solution for patients.

The STENTYS stent maintains constant apposition to the vessel wall, a safer solution compared to conventional stents

---

1 The price of the Offering may be freely set below €10.80 or, so long as purchase orders could be revoked for at least two trading days, may be set above €13.20.
STENTYS

CARDIOLOGISTS ARE EAGER TO BENEFIT FROM THE STENTYS STENT

STENTYS stents proved their efficacy through several clinical trials. APPOSITION II clinical study results, announced on September 22nd, proved STENTYS stent superior to conventional treatments of AMI.

The STENTYS stent received the CE mark in 2010, allowing their sale in the European Union. The heart attack stent market targeted by the Company is estimated at 2.3 billion dollars in 2010 and represents a growing proportion of the coronary stent market.

AN IPO TO IMPOSE STENTYS STENTS AS THE REFERENCE IN THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION

STENTYS aims to become the reference treatment in heart attack and accelerate its products commercialization.

The cash raised from the IPO is intended, in particular, to provide additional resources to:
- Ensure the development and the commercialization of its innovative stents;
- Pursue post-market studies to confirm the benefits of its medical devices;
- Obtain regulatory approvals to allow commercialization of its products in the United States of America and Canada.

A TRANSACTION BACKED BY EXISTING SHAREHOLDERS

In the context of this IPO, Sofinnova and Crédit Agricole Private Equity, historical shareholders of the company, have committed to participate in the capital increase for a maximum amount of 8 M€, representing 35% of the offer (excluding extension clause and over-allotment option on the basis of the mid point of the initial public offering price range).

Public information
The legal and financial documents required to be made available to shareholders may be consulted at the registered office of the Company, 25 rue de Choiseul, 75002 Paris.

Copies of the Prospectus are available free of charge from the Company and from the Lead Underwriter and the Co-underwriter. The Prospectus may be viewed on the websites of the Company (www.stentys.com) and of the AMF (www.amf-france.org).

The attention of investors is drawn to Section 4 “Risk Factors” of the “Document de Base” registered with the AMF and to Section 2 “Risk Factors” contained in the “Note d’opération”, and, in particular, to the specific risks related to the two Company’s licensing agreements.

More information about the company on the website: www.stentys.com

<table>
<thead>
<tr>
<th>SOCIETE GENERALE Corporate &amp; Investment Banking</th>
<th>PiperJaffray</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lead Manager and Bookrunner</td>
<td>Co-Lead Manager</td>
</tr>
<tr>
<td>Société Générale Corporate &amp; Investment Banking</td>
<td>Piper Jaffray</td>
</tr>
</tbody>
</table>

Allegra Finance
Counsel for STENTYS

Citigate Dewe Rogerson
Analysts
Agnès Villeret - Tel: +33 (0)1 53 32 78 95 - agnes.villeret@citigate.fr
Press
Servane Taslé – Tél: +33 (0)1 53 32 78 94 / (0)6 66 58 84 28 – servane.tasle@citigate.fr
Lucie Larguier - Tel: +33 (0)1 53 32 84 75 - lucie.larguier@citigate.fr
Notice

This press release, together with the material set forth herein, does not constitute an offer of securities for sale or the solicitation of an offer to purchase securities of Stentys in any jurisdiction. The dissemination, publication or distribution of this press release in certain countries can constitute a violation of the applicable legal and regulatory provisions. Consequently, persons physically located in these countries and in which this press release is disseminated, distributed or published must obtain information regarding these possible local restrictions, and comply with them.

In particular:

This press release does not constitute an offer to sell or the solicitation of an offer to buy any financial instruments in the United States of America. Securities mentioned in this document have not been and will not be registered under the Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold in the United States of America absent registration or an exemption from the registration requirements of the Securities Act. The Company does not intend to register this offering in all or in part or to make a public offer of securities in the United States of America.

No copy of this press release can be distributed or sent to the United States of America, Italy, Canada, Australia or Japan.

This press release is not an invitation, a solicitation nor is it intended to be an inducement to engage in investment activity within the meaning of the Financial Services and Markets Act 2000, as amended (“FSMA”). This document is directed only at (i) persons outside the United Kingdom; or (ii) persons in the United Kingdom that are (a) persons authorized under FSMA or otherwise having professional experience in matters relating to investments and qualifying as “investment professionals” under article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”); or (b) institutions or corporations qualifying as high net worth persons under Article 49(2)(a) to (d) of the Order; or (c) any other persons to whom this document for the purposes of Section 21 of FSMA can otherwise lawfully be made (all persons mentioned in (i) and (ii) together being referred to as “Relevant Persons”). Any person in the United Kingdom that is not a Relevant Person should not act or rely on this document. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

Société Générale, acting as stabilizing agent, or any institution acting on its behalf (the “Stabilizing Agent”) may, during a period of 30 days following the date on which the offering price is determined, i.e., according to the indicative timetable, from October 29 to November 19, 2010, effect transactions with a view to maintaining the market price of Stentys shares in a manner consistent with applicable laws and regulations and, in particular, EU Commission regulation no 2273/03 of December 22, 2003. However, there is no assurance that the Stabilizing Agent will take any stabilizing action and, if begun, such stabilizing action may be interrupted at any time. Any stabilizing action may affect the price of Stentys shares and could result in market prices for the shares higher than those which might otherwise prevail.